Insulet Corp. logo
PODDInsulet Corp.

Is the EBITDA margin high or low?

The EBITDA margin of 20.20% is 30% above its 5-year average of 15.55%, near the high end of its 5-year range (-4.07%–26.15%).

As of Thursday, June 25, 2026. 9.90% above its 12-month average of 18.38%.

EBITDA|Gross Margin|Operating Margin|Profit Margin|All Metrics
EBITDA Margin

PODD EBITDA Margin

20.20%

Reported quarterly EBITDA margin; no daily interpolation.

+2115.79% 5Y
PODD EBITDA Margin

PODD Average EBITDA Margin Chart

PODD EBITDA Margin

PODD Current vs Average EBITDA Margin Chart

PODD EBITDA Margin Metrics

EBITDA MARGIN

20.20%

EBITDA MARGIN AVG TTM

18.38%

EBITDA MARGIN AVG 3Y

18.97%

EBITDA MARGIN AVG 5Y

17.35%

EBITDA MARGIN AVG 10Y

11.11%

EBITDA MARGIN AVG 15Y

4.02%

EBITDA MARGIN AVG 20Y

-0.63%

CURRENT VS TTM AVG

+9.90%

CURRENT VS 3Y AVG

+6.53%

CURRENT VS 5Y AVG

+16.46%

CURRENT VS 10Y AVG

+81.89%

CURRENT VS 15Y AVG

+402.22%

CURRENT VS 20Y AVG

+3300.95%

PODD Competitors' EBITDA Margin

NAMEMARKET CAPEBITDA MARGINTTM3Y5Y
Insulet Corp. (PODD)$10.31B20.20%18.38%18.97%17.35%
Walgreens Boots Alliance, Inc. (WBA)vs ›$10.37B-7.64%-4.75%-0.21%1.54%
Baxter International Inc. (BAX)vs ›$10.87B6.81%8.65%4.13%9.00%
Charles River Laboratories International, Inc. (CRL)vs ›$9.73B10.23%12.29%18.59%20.64%
Henry Schein, Inc. (HSIC)vs ›$9.38B7.63%7.53%7.47%7.62%
Revvity, Inc. (RVTY)vs ›$11.78B23.20%26.85%28.84%31.56%
Align Technology, Inc. (ALGN)vs ›$12.24B18.98%19.70%20.24%21.46%
Solventum Corporation (SOLV)vs ›$13.01B30.62%24.56%26.05%27.07%
Bio-Rad Laboratories, Inc. (BIO)vs ›$7.57B48.39%-17.53%-54.94%28.49%
Oscar Health, Inc. (OSCR)vs ›$7.56B-3.34%-1.19%-4.96%-19.15%

Margin Comparison

Gross Margin

71.0%

EBITDA Margin

20.2%

Operating Margin

17.5%

Net Margin

10.4%

Formula: EBITDA Margin = (EBITDA / Revenue) × 100

Why EBITDA Margin matters:

  • Removes effects of depreciation policies (D&A)
  • Capital structure neutral (ignores interest)
  • Tax neutral (ignores tax differences)
  • Good proxy for operating cash generation

EBITDA Margin Formula & Definition

EBITDA Margin = EBITDA / Revenue

EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EBITDA Margin FAQ

What is the EBITDA margin for Insulet Corp. (PODD)?
The EBITDA margin for PODD stock is 20.20%.
Is Insulet Corp.'s EBITDA margin high or low?
The EBITDA margin of 20.20% is 30% above its 5-year average of 15.55%, near the high end of its 5-year range (-4.07%–26.15%).
What is the TTM average EBITDA margin for Insulet Corp. (PODD)?
The TTM average EBITDA margin for PODD stock is 18.38%.
What is the 3Y average EBITDA margin for Insulet Corp. (PODD)?
The 3Y average EBITDA margin for PODD stock is 18.97%.
What is the 5Y average EBITDA margin for Insulet Corp. (PODD)?
The 5Y average EBITDA margin for PODD stock is 17.35%.
What is the 10Y average EBITDA margin for Insulet Corp. (PODD)?
The 10Y average EBITDA margin for PODD stock is 11.11%.
What is the 15Y average EBITDA margin for Insulet Corp. (PODD)?
The 15Y average EBITDA margin for PODD stock is 4.02%.
What is the 20Y average EBITDA margin for Insulet Corp. (PODD)?
The 20Y average EBITDA margin for PODD stock is -0.63%.

PODD EBITDA Margin History

DATEEBITDA MARGIN
2026-03-3120.20%
2025-12-3124.29%
2025-09-3022.71%
2025-06-3010.83%
2025-03-3113.88%
2024-12-3123.68%
2024-09-3021.42%
2024-06-3016.64%
2024-03-3119.11%
2023-12-3126.15%
2023-09-3019.14%
2023-06-3014.20%
2023-03-3114.30%
2022-12-3112.60%
2022-09-305.69%
2022-06-30-4.07%
2022-03-3117.77%
2021-12-3120.34%
2021-09-3016.40%
2021-06-300.91%
2021-03-3110.27%
2020-12-317.80%
2020-09-3015.17%
2020-06-3016.97%
2020-03-318.69%
2019-12-3112.48%
2019-09-309.16%
2019-06-308.36%
2019-03-319.84%
2018-12-3113.42%
2018-09-308.05%
2018-06-307.22%
2018-03-314.21%
2017-12-312.37%
2017-09-305.28%
2017-06-300.47%
2017-03-31-1.52%
2016-12-31-0.45%
2016-09-303.91%
2016-06-302.59%
2016-03-31-5.06%
2015-12-31-19.59%
2015-09-30-12.01%
2015-06-30-13.69%
2015-03-31-6.22%
2014-12-311.16%
2014-09-30-6.29%
2014-06-30-30.63%
2014-03-312.14%
2013-12-316.62%
2013-09-30-23.22%
2013-06-30-5.41%
2013-03-31-5.71%
2012-12-31-5.40%
2012-09-30-10.68%
2012-06-30-15.36%
2012-03-31-16.80%
2011-12-31-16.00%
2011-09-30-15.48%
2011-06-30-40.95%
2011-03-31-21.49%
2010-12-31-14.99%
2010-09-30-27.61%
2010-06-30-37.68%
2010-03-31-44.66%
2009-12-31-53.14%
2009-09-30-64.64%
2009-06-30-103.44%
2009-03-31-129.65%
2008-12-31-216.22%
2008-09-30-178.57%
2008-06-30-270.66%
2008-03-31-278.76%
2007-12-31-336.28%
2007-09-30-347.90%
2007-06-30-347.98%
2007-03-31-492.63%
2006-12-31-514.08%
2006-09-30-1414.39%
2006-06-30100.00%
2006-03-31100.00%

Related Metrics

EBITDAGross MarginOperating MarginProfit MarginAll Metrics

About Insulet Corp.

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Acton, MA
5,400 employees
www.insulet.com
Healthcare / Medical - Devices
Sector
Healthcare
Industry
Medical - Devices
CEO
Ashley A. McEvoy
View full financials